Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetylcysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.95 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.59 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | THRB | P10828 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.95 |
| ▸ | THPO | P40225 | 1/20 | 0.95 |
| ▸ | RECQL | P46063 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcysteine SCHEMBL6837834 | 1.00 | MAPT (0.95) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL692009 | 1.00 | MAPT (0.95) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL28278883 | 1.00 | MAPT (0.95) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL28278886 | 1.00 | MAPT (0.95) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL11025039 | 0.98 | MAPT (0.91) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL28790180 | 0.98 | MAPT (0.91) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL28790182 | 0.98 | MAPT (0.91) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3688241 | 0.98 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437350 | 0.98 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437351 | 0.98 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114504425-A | Cold compress patch preparation method, cold compress patch and application method thereof | 湖北舒邦药业有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-112402461-A | Composition for treating autism social interaction disorder | 王益超 | 2021-02-26 | — | — | CN | claimed |
| WO-2020019034-A1 | A TOPICAL SKIN CREAM COMPOSITION | PALMER RAYMOND DENIS (AU) | 2020-01-30 | — | — | WO | claimed |
| US-8608809-B2 | Stable oxidative colouring composition for keratin fibres | KAO GERMANY GMBH (DE) | 2013-12-17 | — | — | US | claimed |
| US-20130180058-A1 | STABLE OXIDATIVE COLOURING COMPOSITION FOR KERATIN FIBRES | KAO GERMANY GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| EP-0185374-B1 | LIQUID DICLOFENAC PREPARATIONS | Merckle GmbH (DE) | 1990-05-02 | — | — | EP | claimed |
| US-4711906-A | MIXTURE OF PROPYLENE GLYCOL AND POLYOXYETHYLENE GLYCOL AND WATER | MERCKLE GMBH (DE) | 1987-12-08 | — | — | US | claimed |
| EP-3774787-B1 | A COMPOUND, A REACTION PRODUCT OF SAID COMPOUND AND PRODUCTION METHODS THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-08-20 | — | — | EP | disclosed |
| US-20250064764-A1 | AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN | Hyloris Pharmaceuticals SA (BE) | 2025-02-27 | — | — | US | disclosed |
| CN-114504425-B | Cold compress preparation method, cold compress and application method thereof | 湖北舒邦药业有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240307481-A1 | COMPOSITIONS AND METHODS FOR IMPROVING EYE FUNCTION | CROSS III WILLIAM H (US) | 2024-09-19 | — | — | US | disclosed |
| US-12083087-B2 | Aqueous formulation comprising paracetamol and ibuprofen | Hyloris Pharmaceuticals SA (BE) | 2024-09-10 | — | — | US | disclosed |
| US-11999821-B2 | Compound, a reaction product of said compound and production methods thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-06-04 | — | — | US | disclosed |
| EP-2908801-A1 | STABLE INJECTABLE COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE | Epifarma Srl (IT) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014064030-A1 | STABLE INJECTABLE COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE | EPIFARMA S.R.L. (IT) | 2014-05-01 | — | — | WO | disclosed |
| US-8608809-B2 | Stable oxidative colouring composition for keratin fibres | KAO GERMANY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| CN-103442737-A | MRI marker, delivery and extraction systems and methods of manufacture and use thereof | UNIV TEXAS | 2013-12-11 | — | — | CN | disclosed |
| US-20130180058-A1 | STABLE OXIDATIVE COLOURING COMPOSITION FOR KERATIN FIBRES | KAO GERMANY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2608763-A2 | STABLE OXIDATIVE COLOURING COMPOSITION FOR KERATIN FIBRES | Kao Germany GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025435-A2 | STABLE OXIDATIVE COLOURING COMPOSITION FOR KERATIN FIBRES | KPSS-KAO PROFESSIONAL SALON SERVICES GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999821-B2 | Compound, a reaction product of said compound and production methods thereof | COASY, CYP2C9, CYP2C19 | PTGS2 368/4885ACE 258/4885CA2 3392/4885 |
| US-20130180058-A1 | STABLE OXIDATIVE COLOURING COMPOSITION FOR KERATIN FIBRES | KRT18, GCLC, GLO1 | PTGS2 626/4885ACE 1167/4885CA2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.